DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

CFRA Upgrades Quest Diagnostics to Strong Buy, Raises Price Target to $140

CFRA analyst Paige Meyer upgrades Quest Diagnostics (NYSE:DGX) from Hold to Strong Buy and raises the price target from $116 to $140.

Benzinga · 03/05/2020 17:14

CFRA analyst Paige Meyer upgrades Quest Diagnostics (NYSE:DGX) from Hold to Strong Buy and raises the price target from $116 to $140.